Difficulty: Medium
Average Score: 92%
Practice
A 54-year-old woman with a history of left-sided breast cancer has been in remission for 5 years following paclitaxel therapy coupled with surgical resection. She has now noticed a new lump in her left breast close to where the original tumor was excised. A biopsy reveals recurring cancer. After talking with her physician, she decided to undergo more chemotherapy. Her physician prescribes a drug, which interferes with microtubules. Which is a chemotherapy drug that disrupts the microtubule assembly?
Correct answer
D
Rationale
The correct answer is D) Vincristine. Vincristine is a chemotherapy drug that disrupts microtubule assembly, specifically targeting tubulin polymerization. This action inhibits the formation of the mitotic spindle, leading to cell cycle arrest and ultimately cell death.
Option A) Cisplatin is a platinum-based chemotherapy drug that acts by forming DNA crosslinks, leading to DNA damage. It does not disrupt microtubule assembly like Vincristine.
Option B) Docetaxel is a taxane chemotherapy drug that also interferes with microtubules but acts by stabilizing microtubules rather than disrupting their assembly.
Option C) Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor pathway and is not associated with microtubule disruption.
Educationally, understanding the mechanisms of action of chemotherapy drugs is crucial for healthcare providers to make informed treatment decisions for patients with cancer. Knowing how specific drugs target different cellular processes allows for personalized and effective treatment strategies, minimizing side effects and optimizing outcomes for patients undergoing chemotherapy.
Option A) Cisplatin is a platinum-based chemotherapy drug that acts by forming DNA crosslinks, leading to DNA damage. It does not disrupt microtubule assembly like Vincristine.
Option B) Docetaxel is a taxane chemotherapy drug that also interferes with microtubules but acts by stabilizing microtubules rather than disrupting their assembly.
Option C) Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor pathway and is not associated with microtubule disruption.
Educationally, understanding the mechanisms of action of chemotherapy drugs is crucial for healthcare providers to make informed treatment decisions for patients with cancer. Knowing how specific drugs target different cellular processes allows for personalized and effective treatment strategies, minimizing side effects and optimizing outcomes for patients undergoing chemotherapy.